Brief: Imunon Files For Mixed Shelf Of Up To $75 Mln
Imunon Inc reports results for the quarter ended in March - Earnings Summary
Brief: IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Imunon Inc expected to post a loss of 57 cents a share - Earnings Preview
Imunon Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: IMUNON Reports Compliance With Nasdaq Listing Requirements
Imunon Inc reports results for the quarter ended in December - Earnings Summary
Imunon Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: IMUNON Receives $1.3 Mln from Sale of its New Jersey Net Operating Losses
Brief: Biotech Firm IMUNON Files IND Application To Begin Human Testing Of IMNN-101
Brief: IMUNON Announces Leadership Change
Brief: Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Brief: Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Brief: Imunon Inc Received Notice From Nasdaq That Co Has Not Been Compliance With The Minimum Bid Price Requirement
Brief: IMUNON Says First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001
Brief: Imunon Reports Interim Progression-Free Survival And Overall Survival Data In Phase 1/2 Ovation 2 Study In Advanced Ovarian Cancer
Brief: Imunon Enters Into Crada For Preclinical Studies Of Placcine Modality In Preventive Vaccines Against Lassa Virus
Imunon Inc reports results for the quarter ended in June - Earnings Summary
Brief: Imunon Q2 EPS USD -0.61